The cell therapy manufacturing market is anticipated to grow at an annualized rate of over 12%, claims Roots Analysis
Given the consistent research efforts and continuous growth of the cell therapies development pipeline, this upcoming therapeutic segment is expected to represent one of the highest valued segments of the biopharmaceutical industry in the foreseen future
LONDON, Feb. 28, 2023 /PRNewswire/ -- Roots Analysis has announced the addition of "Cell Therapy Manufacturing Market (5th Edition), 2022-2035" report to its list of offerings.
Owing to the intricacies associated with the manufacturing processes, requirement for advanced production facilities and the growing demand for cell therapy products, developers are actively outsourcing certain production operations, in addition to expanding their in-house capabilities.
To order this 649 page report, which features 245+ figures and 285+ tables, please visit https://www.rootsanalysis.com/reports/view_document/cell-therapy-manufacturing/285.html
Key Market Insights
Around 240 organizations claim to be engaged in contract manufacturing of cell therapies
The current market landscape is dominated by industry players, which constitute 70% of the total number of stakeholders. It is worth mentioning that, amongst these, over 39% companies are small firms.
340+ production facilities dedicated to cell therapies have been established worldwide
North America has emerged as a key manufacturing hub for cell therapies, featuring the presence of nearly 46% manufacturing facilities; this is followed by Europe (28%). Other emerging regions include China, Japan, Singapore and Australia.
65+ cell therapy manufacturers are focused on immune cell and stem cell therapies
Most of the players in this domain are focused on manufacturing of T cell therapies, primarily CAR-T therapies, while stem cell therapy manufacturers are primarily engaged in the production of adult stem cells and mesenchymal stem cell therapies
Presently, more than 100 companies carry out manufacturing at all scales of operation.
Nearly 54% players have the required capabilities for commercial scale manufacturing. It is worth noting that all industry and non-industry players manufacture cell therapies required for clinical purposes.
45+ companies offer automated and closed systems to cell therapy developers
More than 70 automated and closed systems are being used for cell therapy manufacturing. Nearly 60% automation technologies have been developed for processing and manufacturing adult stem cells, followed by those focused on T cells (53%).
1,038+ clinical trials evaluating cell therapies have been registered post 2019, worldwide
The clinical research activity (in terms of number of trials registered) increased at a CAGR of 73%, during the period 2019-2022. Of the total number of trials, close to 94% studies are presently active. Amongst the active trials, 76% were observed to be currently recruiting.
Over 260 partnerships were established in this domain, during the period 2016-2022
A large proportion (28%) of the partnerships were related to cell therapy manufacturing, followed by mergers and acquisitions (19%), and product development and commercialization agreements (9%).
Expansion activity in this domain has grown at a CAGR of 70%, between 2017 and 2022
More than 110 facility expansions were reported during the given time period. Over 80% instances were related to the establishment of new facilities, followed by those involving the expansion of existing facilities (19%).
Initiatives undertaken by big pharma players have increased at a CAGR of 58%, during 2017-2022
Several big pharma players have carried out initiatives focused on cell therapy manufacturing. Gilead sciences, Takeda Pharmaceutical and Novartis are some of the prominent big pharma players in this domain.
Currently available global cell therapy manufacturing capacity is estimated to be over 5.44 billion sq. ft. of dedicated cleanroom area
The maximum (48%) installed capacity (in terms of cleanroom area) belongs to companies based in North America; the region has a higher number of players, which have multiple production facilities. This is followed by Asia Pacific (41%) and Europe (12%).
The demand for cell therapies is anticipated to grow at a CAGR of 16%, during 2022-2035
Presently, the clinical demand for stem cell and CAR-T cell-based products is the highest; this trend is unlikely to change in the foreseen future as well. On the other hand, the demand for NK cell and dendritic cell therapies is expected to grow at a relatively faster pace, over the next decade.
By 2035, the market for commercial scale cell therapy manufacturing is likely to grow at an annualized rate of 19%
Currently, North America and Europe capture more than 55% share of the overall market. Specifically, the cell therapy manufacturing market in Asia Pacific is driven by countries, such as China, Japan, South Korea, India and Singapore. It is worth noting that the current market in Asia Pacific is primarily driven by the clinical demand for cell therapies.
To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/285/request-sample.html
Frequency Asked Questions
The financial opportunity associated with the cell therapy manufacturing market has been analyzed across the following segments:
The report also features inputs from eminent industry stakeholders, according to whom, the manufacturing of cell therapies is largely being outsourced due to exorbitant costs associated with the setting-up of in-house expertise. The report includes detailed transcripts of discussions held with the following experts:
The research includes profiles of key players (industry and non-industry; listed below), featuring a brief overview of the company / organization, along with details related to its manufacturing facilities, service portfolio, recent developments and an informed future outlook.
For additional details, please visit
You may also be interested in the following titles:
View original content:https://www.prnewswire.co.uk/news-releases/the-cell-therapy-manufacturing-market-is-anticipated-to-grow-at-an-annualized-rate-of-over-12-claims-roots-analysis-301757495.html